Elise M Blanchet1, David Taieb2, Corina Millo3, Victoria Martucci1, Clara C Chen4, Maria Merino5, Peter Herscovitch3, Karel Pacak6. 1. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland. 2. La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France. 3. Positron Emission Tomography Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland. 4. Nuclear Medicine Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland; and. 5. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 6. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland karel@mail.nih.gov.
Abstract
UNLABELLED: (18)F-FDG PET/CT has been proven to be a highly sensitive method for pheochromocytomas/paragangliomas (PHEOs/PGLs) associated with succinate dehydrogenase (SDH) mutations. This finding has been attributed to altered tumor cell metabolism resulting from these mutations and does not provide additional prognostic information to genotype. Therefore, identification of new biomarkers for aggressiveness is needed. A high Ki-67 index was proposed to be an additional prognostic factor. This pilot study aimed to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET/CT, a PET proliferation tracer, as a potential imaging agent in a series of 12 PHEO/PGL patients with different genetic backgrounds, to compare (18)F-FLT uptake with (18)F-FDG PET/CT, and to evaluate classic factors of aggressiveness. METHODS: Twelve patients (7 metastatic and 5 nonmetastatic) were prospectively evaluated with (18)F-FDG and (18)F-FLT and followed for at least 2 y after the initial imaging work-up. Uptake was assessed at a lesion level, visually and quantitatively by maximum standardized uptake values (SUVmax) for both tracers. (18)F-FLT uptake was compared with risk factors known to be linked with a poor prognosis in PGLs (SDHB-mutated status, lesion size, dopaminergic phenotype) and with (18)F-FDG uptake. RESULTS: In 12 patients, 77 lesions were assessed. All lesions had low (18)F-FLT uptake (median SUVmax, 2.25; range, 0.7-4.5). There was no apparent superiority of (18)F-FLT uptake in progressive lesions, and most of the lesions showed a mismatch, with high (18)F-FDG uptake (median SUVmax, 10.8; range, 1.1-79.0) contrasting with low (18)F-FLT uptake. CONCLUSION: This study suggests that PHEOs/PGLs-even those that progress-do not exhibit intense (18)F-FLT uptake. It provides the first in vivo demonstration that proliferation may not be a major determinant of (18)F-FDG uptake in these tumors. These findings provide new insight into the biologic behavior of PGL and suggest that antiproliferative agents may be suboptimal for treatment of these tumors.
UNLABELLED: (18)F-FDG PET/CT has been proven to be a highly sensitive method for pheochromocytomas/paragangliomas (PHEOs/PGLs) associated with succinate dehydrogenase (SDH) mutations. This finding has been attributed to altered tumor cell metabolism resulting from these mutations and does not provide additional prognostic information to genotype. Therefore, identification of new biomarkers for aggressiveness is needed. A high Ki-67 index was proposed to be an additional prognostic factor. This pilot study aimed to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET/CT, a PET proliferation tracer, as a potential imaging agent in a series of 12 PHEO/PGLpatients with different genetic backgrounds, to compare (18)F-FLT uptake with (18)F-FDG PET/CT, and to evaluate classic factors of aggressiveness. METHODS: Twelve patients (7 metastatic and 5 nonmetastatic) were prospectively evaluated with (18)F-FDG and (18)F-FLT and followed for at least 2 y after the initial imaging work-up. Uptake was assessed at a lesion level, visually and quantitatively by maximum standardized uptake values (SUVmax) for both tracers. (18)F-FLT uptake was compared with risk factors known to be linked with a poor prognosis in PGLs (SDHB-mutated status, lesion size, dopaminergic phenotype) and with (18)F-FDG uptake. RESULTS: In 12 patients, 77 lesions were assessed. All lesions had low (18)F-FLT uptake (median SUVmax, 2.25; range, 0.7-4.5). There was no apparent superiority of (18)F-FLT uptake in progressive lesions, and most of the lesions showed a mismatch, with high (18)F-FDG uptake (median SUVmax, 10.8; range, 1.1-79.0) contrasting with low (18)F-FLT uptake. CONCLUSION: This study suggests that PHEOs/PGLs-even those that progress-do not exhibit intense (18)F-FLT uptake. It provides the first in vivo demonstration that proliferation may not be a major determinant of (18)F-FDG uptake in these tumors. These findings provide new insight into the biologic behavior of PGL and suggest that antiproliferative agents may be suboptimal for treatment of these tumors.
Authors: P N Span; J U Rao; S B J Oude Ophuis; J W M Lenders; F C G J Sweep; P Wesseling; B Kusters; F H van Nederveen; R R de Krijger; A R M M Hermus; H J L M Timmers Journal: Endocr Relat Cancer Date: 2011-04-28 Impact factor: 5.678
Authors: Pierre de Wailly; Luigi Oragano; Francois Radé; Anthony Beaulieu; Vincent Arnault; Pierre Levillain; Jean Louis Kraimps Journal: Langenbecks Arch Surg Date: 2011-11-09 Impact factor: 3.445
Authors: Graeme Eisenhofer; Jacques W M Lenders; Gabriele Siegert; Stefan R Bornstein; Peter Friberg; Dragana Milosevic; Massimo Mannelli; W Marston Linehan; Karen Adams; Henri J Timmers; Karel Pacak Journal: Eur J Cancer Date: 2011-10-28 Impact factor: 9.162
Authors: Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Kathryn S King; Jyotsna U Rao; Robert A Wesley; Karen T Adams; Karel Pacak Journal: J Natl Cancer Inst Date: 2012-04-18 Impact factor: 13.506
Authors: D J Pinato; R Ramachandran; S T K Toussi; M Vergine; N Ngo; R Sharma; T Lloyd; K Meeran; F Palazzo; N Martin; B Khoo; R Dina; T M Tan Journal: Br J Cancer Date: 2012-12-20 Impact factor: 7.640